Eptinezumab

What is Eptinezumab?[edit | edit source]

Eptinezumab (Vyepti), is a calcitonin gene-related peptide antagonist.

What are the uses of this medicine?[edit | edit source]

Eptinezumab (Vyepti), is used in the prevention of migraine in adults.

How does this medicine work?[edit | edit source]

Eptinezumab-jjmr is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor.

Who Should Not Use this medicine?[edit | edit source]

It is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients in it.

Is this medicine FDA approved?[edit | edit source]

The U.S. Food and Drug Administration (FDA) approved eptinezumab

How should this medicine be used?[edit | edit source]

Recommended dosage:

Recommended dosage is 100 mg as an intravenous infusion over approximately 30 minutes every 3 months. Some patients may benefit from a dosage of 300 mg.

Administration: Vyepti will be given by a healthcare provider in a healthcare setting. Must dilute before use. Dilute only in 100 mL of 0.9% Sodium Chloride Injection, USP. Vyepti is given by intravenous (IV) infusion in your vein. Vyepti will be given over 30 minutes every 3 months.

What are the dosage forms and brand names of this medicine?[edit | edit source]

Vyepti is a clear to slightly opalescent, colorless to brownish-yellow solution available as follows:Injection: 100 mg/mL in a single-dose vial .
Vyepti is the brand name.

What side effects can this medication cause?[edit | edit source]

The most common side effects of this medicine include:

stuffy nose and scratchy throat
allergic reactions

Less common,but serious side effects may include:

Nasopharyngitis
Allergic reactions
swelling of your face, lips, tongue or throat
trouble breathing
hives
redness in your face
stuffy nose and scratchy throat
Serious hypersensitivity reactions may occur.

What special precautions should I follow?[edit | edit source]

Before you receive Vyepti, tell your healthcare provider about all of your medical conditions, including if you:

are pregnant or plan to become pregnant. It is not known if Vyepti will harm your unborn baby.
are breastfeeding or plan to breastfeed. It is not known if Vyepti passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby while using Vyepti.
Inform patients about the signs and symptoms of hypersensitivity reactions and that these reactions can occur with VYEPTI. Advise patients to contact their healthcare provider immediately if signs or symptoms of hypersensitivity reactions occur.

What to do in case of emergency/overdose?[edit | edit source]

In case of overdose, call the poison control helpline of your country. In the United States, call 1-800-222-1222.

Overdose related information is also available online at poisonhelp.org/help.
In the event that the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services. In the United States, call 911.
Call your healthcare provider or get emergency medical help right away if you have any of the following symptoms of any allergic reaction like rash or hives or difficulty breathing

Can this medicine be used in pregnancy?[edit | edit source]

There are no adequate data on developmental risks associated with the use of Vyepti in pregnant women.

Can this medicine be used in children?[edit | edit source]

Safety and effectiveness in pediatric patients have not been established.

What should I know about storage and disposal of this medication?[edit | edit source]

Gently invert the Vyepti solution to mix completely.
Do not shake.
Following dilution, Vyepti solution must be infused within 8 hours.
During this time, Vyepti solution should be stored at room temperature, 20°C to 25°C (68°F to 77°F).
Do not freeze.

Eptinezumab Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.